ARNUITY ELLIPTA (GlaxoSmithKline Australia Pty Ltd)
Product name
ARNUITY ELLIPTA
Date registered
Evaluation commenced
Decision date
Approval time
200 working days (255)
Active ingredients
fluticasone furoate
Registration type
EOI
Indication
ARNUITY ELLIPTA (powder for inhalation) is now also indicated for the maintenance treatment of asthma in patients aged 5 years to less than 12 years.